The Efficacy and Safety of Eravacycline in the Management of Infections: A Single-Center Experience
Antibiotics · 07.05.2026 · 15 (5) · 474
DOI: 10.3390/antibiotics15050474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 07.05.2026. Verfasst von Narendran Koomanan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Eravacycline is a fluorocycline antibiotic increasingly used for drug-resistant or difficult-to-treat infections, including off-label indications, with limited real-world clinical data. This study aimed to characterize the effectiveness, safety, and overall risk-benefit profile of eravacycline using an adapted Desirability of Outcome Ranking (DOOR) framework.
Methods
We conducted a retrospective, single-center observational study of adult patients who received ≥48 h of eravacycline at an academic medical center between May 2022 and October 2023. Clinical response was assessed at the end of therapy, alongside 30-day all-cause mortality. Treatment-emergent adverse events (TEAEs) were recorded and normalized per 100 eravacycline-days. An adapted DOOR framework integrated efficacy, toxicity and mortality into an ordinal composite outcome, with analyses stratified by pathogen and site of infection.
Results
A total of 140 patients contributed 151 eravacycline courses. Intra-abdominal (41.7%) and lower respiratory tract infections (27.8%) were the most common indications. Treatment success was observed in 69.5% of courses, while 30-day all-cause mortality was 23.6%. TEAEs occurred in 52.3% of courses and frequently led to eravacycline discontinuation. Exposure-normalized TEAE rates were highest in shorter courses, with gastrointestinal intolerance predominating early, while hepatoxicity and coagulation abnormalities were more frequent with intermediate treatment durations. DOOR analysis demonstrated highly desirable outcomes in 48.3% of courses, with more favorable profiles observed in carbapenem-resistant Enterobacterales (CRE), vancomycin-resistant Enterococci (VRE) and nontuberculous mycobacteria (NTM) infections. Bloodstream infections were associated with less desirable outcomes.
Conclusions
Eravacycline demonstrated meaningful real-world activity across complex infections but was limited by frequent toxicity. The DOOR framework provided a patient-centered context for organism- and site-specific risk-benefit assessment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmacy, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
- SingHealth Duke-NUS Medicine Academic Clinical Programme, 8 College Road, Singapore 169857, Singapore.
- Emerging Infectious Disease Program, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
ORCID-Profile: Yvonne Peijun Zhou
Zitieren
APA
Koomanan, N., Zhou, Y. P., & Kwa, A. L. H. (2026). The Efficacy and Safety of Eravacycline in the Management of Infections: A Single-Center Experience. Antibiotics, 15(5), 474. https://doi.org/10.3390/antibiotics15050474
Vancouver
Koomanan N, Zhou YP, Kwa ALH. The Efficacy and Safety of Eravacycline in the Management of Infections: A Single-Center Experience. Antibiotics. 2026;15(5):474. doi:10.3390/antibiotics15050474
BibTeX
@article{Koomanan2026,
author = {Koomanan, Narendran and Zhou, Yvonne Peijun and Kwa, Andrea Lay Hoon},
title = {The Efficacy and Safety of Eravacycline in the Management of Infections: A Single-Center Experience},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {5},
pages = {474},
doi = {10.3390/antibiotics15050474}
}
EUVIMED